The FDA has officially taken effect of an Investigational New Drug (IND) application for mitragynine, the primary psychoactive compound in Mitragyna speciosa (kratom), opening the door for human safety trials.
Moving from animal models to human subjects
While interest in kratom as a tool for managing opioid withdrawal and pain has surged, the compound in isolation has never been studied in humans. Preclinical work conducted by researchers at the University of Florida, the National Institute on Drug Abuse (NIDA), and the National Center for Advancing Translational Sciences (NCATS) demonstrated that mitragynine administration across several doses did not raise significant safety concerns in animal models.
Research indicates that the potential therapeutic effects of the compound are likely driven by the slow conversion of mitragynine within the body. This distinction is critical as investigators move toward the first randomized, double-blind, placebo-controlled study to assess the safety and tolerability of the purified formulation.
Expanding treatment options under the HEAL Initiative
This phase I clinical trial is a core component of the NIH Helping to End Addiction Long-term (HEAL) Initiative. The goal is to expand treatment options for the millions of Americans struggling with opioid use disorder, a crisis that has contributed to historically high overdose mortality rates.
Scientists at NIH and the University of Florida developed the purified formulation specifically for this trial, building on the preclinical foundation that led to the IND submission. This work represents a major shift from observing anecdotal kratom use to rigorously testing a controlled, purified isolate in a clinical setting.
Successful completion of these safety trials could establish a new, evidence-based pharmacological path for opioid recovery and addiction management.
Source: NIH research clears way for study of experimental treatment for opioid use disorder
Domain: nih.gov
Comments load interactively on the live page.